Abstract
Early T stage colorectal cancers (CRC) that invade lymph nodes (Stage IIIA) are greatly under-represented in large-scale genomic mapping projects such as TCGA datasets. We retrieved 10 Stage IIIA CRC cases, matched these to 16 Stage 1 CRC cases (T1 depth without lymph node metastasis) and carried out deep sequencing of 409 genes using the IonTorrent system. Tumour mutational burdens (TMB) ranged from 2.4-77.2/Mb sequenced. Using mean TMB as a cut-point to define groups, TMB-low (TMB-L) specimens showed higher frequency of KRAS and TP53 mutations in Stage IIIA compared to Stage I, consistent with TCGA data. TMB-High (TMB-H) specimens consisted of both microsatellite instable high (MSI-H) and microsatellite stable (MSS) genotypes. Comparison of TMB-H with TMB-L groups revealed clear differences in mutations of ATM, KDM5C, PIK3CA and APC. APC was less frequently mutated in the TMB-H group although variant composition was more diverse. Variants in ATM were restricted to the TMB-H group, and in four of five MSS specimens we observed the co-occurrence of mutations in homologous recombination repair (HRR) genes in either two of ATM, CDK12, PTEN or ATR, with at least one of these being a truncating mutation. No MSI-H specimens carried nonsense mutations in these genes. These findings add to our knowledge of early T stage CRC and highlight a potential therapeutic vulnerability in the HRR pathway of TMB-H MSS CRC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MPM and AE acknowledge project funding support from Colorectal Surgical Society ANZ Foundation. JL, AE and MPM acknowledge funding support from Cancer Council NSW (RG20-10). PS is the recipient of a Cancer Institute NSW early career fellowship (2019/ECF011). MPM is supported by Bowel Cancer Research Foundation Australia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human Research Ethics Committee of Northern Sydney Local Health District gave ethical approval for this work (RESP/18/248).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors